fatnews.com

SEARCH

Saturday, November 01, 2014

BELVIQ (LORCASERIN)

Belviq (lorcaserin) increases risk of depression 1.9-fold

Belviq (lorcaserin), a weight loss drug, is associated with a 1.9-fold increase in the risk of depression according to a paper looking at side effects of the drug written by James DiNicolantonio, PharmD and others.

This finding was based on a pooled analysis of three randomized controlled trials testing lorcaserin 10 mg twice daily versus placebo.

Read the entire article | Email this article
Posted by Larry Hobbs on Sat, Nov 01, 2014 1:28 pm | [0] comments

BELVIQ (LORCASERIN)

Belviq (lorcaserin) increases risk of heart attack, cardiovascular death and non-fatal stroke 2-fold

Belviq (lorcaserin), a weight loss drug, in one study was associated with a “twofold increased rate of cardiovascular death, non-fatal myocardial infarction [heart attack] or non-fatal stroke” according to a paper looking at side effects of the drug written by James DiNicolantonio, PharmD and others.

“In BLOOM-diabetes mellitus (DM), there was also an increase in adverse events related to ischaemic heart disease with lorcaserin [Belviq, a weight loss drug,] versus placebo (0.6% vs 0.4%, respectively) with a twofold increased rate of cardiovascular death, non-fatal myocardial infarction [heart attack] or non-fatal stroke,” notes the paper.

Read the entire article | Email this article
Posted by Larry Hobbs on Sat, Nov 01, 2014 1:08 pm | [0] comments

BELVIQ (LORCASERIN)

Belviq (lorcaserin) increases risk of primary pulmonary hypertension 1.4-fold

Belviq (lorcaserin), a weight loss drug, was associated with a 1.4-fold increased risk of ‘possible’ primary pulmonary hypertension according to a paper looking at side effects of the drug written by James DiNicolantonio, PharmD and others.

The difference was not statistically significant. The p-value was 0.16, meaning that there was a 16% chance that this difference was due to random chance and an 84% chance that the difference was due to the drug.

“Lastly, there may be an increase in ‘possible’ primary pulmonary hypertension with lorcaserin,” the paper notes.

“Indeed, data derived from a pooled analysis of both BLOOM and BLOSSOM (n=3470), using a 35 mm Hg or greater increase in systolic arterial pulmonary pressure as a cut-off for ‘possible’ primary pulmonary hypertension, yield an increased risk with lorcaserin versus placebo (OR 1.41; 95% CI 0.87 to 2.27, p=0.16). Although not a statistically significant finding, primary pulmonary hypertension is a very serious clinical adverse effect with a high mortality rate, and thus any possibility of an increased risk should be taken seriously.”

Read the entire article | Email this article
Posted by Larry Hobbs on Sat, Nov 01, 2014 12:50 pm | [0] comments

BELVIQ (LORCASERIN)

Belviq (lorcaserin) increases risk of mitral regurgitation 2-fold

Belviq (lorcaserin), a weight loss drug, was associated with a 2-fold increased risk of moderate or greater mitral regurgitation after one-year of drug use according to a paper looking at side effects of the drug written by James DiNicolantonio, PharmD and others.

“Despite the fact that the lorcaserin package insert states that it does not cause a significant increase in FDA-defined valvulopathy, defined as mitral regurgitation greater than mild or aortic regurgitation greater than trace (pooled relative risk (RR) of the phase 3 echocardiographic data: 1.16; 95% CI 0.81 to 1.67), a look at the FDA Medical Review states that lorcaserin causes a significant increase in moderate or greater mitral regurgitation at week 52 (RR 1.95; 95% CI 1.05 to 3.59, p value not stated) and (RR 1.88; 95% CI 1.02 to 3.47, p=0.04) based on our forest plot) (figure 1),” the paper notes.

“These data were based on a meta-analysis of three randomised controlled trials testing lorcaserin 10 mg twice daily versus placebo.”

Read the entire article | Email this article
Posted by Larry Hobbs on Sat, Nov 01, 2014 12:34 pm | [0] comments

Saturday, June 22, 2013

BELVIQ (lorcaserin)

Belviq (lorcaserin) side effects: Hypoglycemia in 29% of patients vs 21% with placebo

Hypoglycemia was reported in 29.3% of patients given the weight loss drug, Belviq (lorcaserin), versus 21% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.

Read the entire article | Email this article
Posted by Larry Hobbs on Sat, Jun 22, 2013 2:59 pm | [0] comments

BELVIQ (lorcaserin)

Belviq (lorcaserin) side effects: Headache in 16.8% of patients vs 10.1% with placebo

Headache was reported in 16.8% of patients given the weight loss drug, Belviq (lorcaserin), versus 10.1% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.

Read the entire article | Email this article
Posted by Larry Hobbs on Sat, Jun 22, 2013 2:50 pm | [0] comments

BELVIQ (lorcaserin)

Belviq (lorcaserin) side effects: Headache in 14.5% of patients vs 7.1% with placebo

Headache were reported in 14.5% of patients given the weight loss drug, Belviq (lorcaserin), versus 7.1% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.

Read the entire article | Email this article
Posted by Larry Hobbs on Sat, Jun 22, 2013 2:40 pm | [0] comments

BELVIQ (lorcaserin)

Belviq (lorcaserin) side effects: Upper respiratory infection 13.7% of patients, 12.3% with placebo

Upper respiratory tract infection was reported in 13.7% of patients given the weight loss drug, Belviq (lorcaserin), versus 12.3% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.

Read the entire article | Email this article
Posted by Larry Hobbs on Sat, Jun 22, 2013 2:30 pm | [0] comments

BELVIQ (lorcaserin)

Belviq (lorcaserin) side effects: Inflammation of nasal passages 13% of patients, 12% with placebo

Nasopharyngitis or inflammation of the nasal passages and of the upper part of the pharynx was reported in 13% of patients given the weight loss drug, Belviq (lorcaserin), versus 12% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.

Read the entire article | Email this article
Posted by Larry Hobbs on Sat, Jun 22, 2013 2:27 pm | [0] comments

BELVIQ (lorcaserin)

Belviq (lorcaserin) side effects: Back pain in 11.7% of patients vs 7.9% with placebo

Back pain was reported in 11.7% of patients given the weight loss drug, Belviq (lorcaserin), versus 7.9% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.

Read the entire article | Email this article
Posted by Larry Hobbs on Sat, Jun 22, 2013 2:26 pm | [0] comments

BELVIQ (lorcaserin)

Belviq (lorcaserin) side effects: Nasopharyngitis in 11.3% of patients vs 9.9% with placebo

Nasopharyngitis, which is infection or inflammation of the throat and nasal passages, was reported in 11.3% of patients given the weight loss drug, Belviq (lorcaserin), versus 9.9% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.

Read the entire article | Email this article
Posted by Larry Hobbs on Sat, Jun 22, 2013 2:26 pm | [0] comments

BELVIQ (lorcaserin)

Belviq (lorcaserin) side effects: Nausea in 9.4% of patients vs 7.9% with placebo

Nausea was reported in 9.4% of patients given the weight loss drug, Belviq (lorcaserin), versus 7.9% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.

Read the entire article | Email this article
Posted by Larry Hobbs on Sat, Jun 22, 2013 2:24 pm | [0] comments

BELVIQ (lorcaserin)

Belviq (lorcaserin) side effects: Urinary tract infection in 9% of patients vs 6% with placebo

Urinary tract infection was reported in 9% of patients given the weight loss drug, Belviq (lorcaserin), versus 6% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.

Read the entire article | Email this article
Posted by Larry Hobbs on Sat, Jun 22, 2013 2:23 pm | [0] comments

BELVIQ (lorcaserin)

Belviq (lorcaserin) side effects: Muscle spasms in 4.7% of patients vs 3.6% with placebo

Muscle spasms were reported in 4.7% of patients given the weight loss drug, Belviq (lorcaserin), versus 3.6% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.

Read the entire article | Email this article
Posted by Larry Hobbs on Sat, Jun 22, 2013 2:22 pm | [0] comments

BELVIQ (lorcaserin)

Belviq (lorcaserin) side effects: Dizziness in 8.5% of patients vs 3.8% with placebo

Dizziness was reported in 8.5% of patients given the weight loss drug, Belviq (lorcaserin), versus 3.8% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.

Read the entire article | Email this article
Posted by Larry Hobbs on Sat, Jun 22, 2013 2:22 pm | [0] comments

BELVIQ (lorcaserin)

Belviq (lorcaserin) side effects: Nausea in 8.3% of patients vs 5.3% with placebo

Nausea was reported in 8.3% of patients given the weight loss drug, Belviq (lorcaserin), versus 5.3% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.

Read the entire article | Email this article
Posted by Larry Hobbs on Sat, Jun 22, 2013 2:20 pm | [0] comments

BELVIQ (lorcaserin)

Belviq (lorcaserin) side effects: Cough in 8.2% of patients vs 4.4% with placebo

Cough were reported in 8.2% of patients given the weight loss drug, Belviq (lorcaserin), versus 4.4% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.

Read the entire article | Email this article
Posted by Larry Hobbs on Sat, Jun 22, 2013 2:19 pm | [0] comments

BELVIQ (lorcaserin)

Belviq (lorcaserin) side effects: Fatigue in 7.4% of patients vs 4% with placebo

Fatigue was reported in 7.4% of patients given the weight loss drug, Belviq (lorcaserin), versus 4% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.

Read the entire article | Email this article
Posted by Larry Hobbs on Sat, Jun 22, 2013 2:18 pm | [0] comments

BELVIQ (lorcaserin)

Belviq (lorcaserin) side effects: Fatigue in 7.2% of patients vs 3.6% with placebo

Fatigue was reported in 7.2% of patients given the weight loss drug, Belviq (lorcaserin), versus 3.6% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.

Read the entire article | Email this article
Posted by Larry Hobbs on Sat, Jun 22, 2013 2:15 pm | [0] comments

BELVIQ (lorcaserin)

Belviq (lorcaserin) side effects: Dizziness in 7% of patients vs 6.3% with placebo

Dizziness were reported in 7% of patients given the weight loss drug, Belviq (lorcaserin), versus 6.3% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.

Read the entire article | Email this article
Posted by Larry Hobbs on Sat, Jun 22, 2013 2:13 pm | [0] comments

BELVIQ (lorcaserin)

Belviq (lorcaserin) side effects: Urinary tract infection in 6.5% of patients vs 5.4% with placebo

Urinary tract infection was reported in 6.5% of patients given the weight loss drug, Belviq (lorcaserin), versus 5.4% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.

Read the entire article | Email this article
Posted by Larry Hobbs on Sat, Jun 22, 2013 2:12 pm | [0] comments

BELVIQ (lorcaserin)

Belviq (lorcaserin) side effects: Diarrhea in 6.5% of patients vs 5.6% with placebo

Diarrhea was reported in 6.5% of patients given the weight loss drug, Belviq (lorcaserin), versus 5.6% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.

Read the entire article | Email this article
Posted by Larry Hobbs on Sat, Jun 22, 2013 2:10 pm | [0] comments

BELVIQ (lorcaserin)

Belviq (lorcaserin) side effects: Back pain in 6.3% of patients vs 5.6% with placebo

Back pain was reported in 6.3% of patients given the weight loss drug, Belviq (lorcaserin), versus 5.6% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.

Read the entire article | Email this article
Posted by Larry Hobbs on Sat, Jun 22, 2013 2:08 pm | [0] comments

BELVIQ (lorcaserin)

Belviq (lorcaserin) side effects: Constipation in 5.8% of patients vs 3.9% with placebo

Constipation was reported in 5.8% of patients given the weight loss drug, Belviq (lorcaserin), versus 3.9% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.

Read the entire article | Email this article
Posted by Larry Hobbs on Sat, Jun 22, 2013 2:00 pm | [0] comments

BELVIQ (lorcaserin)

Belviq (lorcaserin) side effects: Hypertension in 5.1% of patients vs 3.2% with placebo

Hypertension were reported in 5.1% of patients given the weight loss drug, Belviq (lorcaserin), versus 3.2% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.

Read the entire article | Email this article
Posted by Larry Hobbs on Sat, Jun 22, 2013 1:55 pm | [0] comments

BELVIQ (lorcaserin)

Belviq (lorcaserin) side effects: Dry Mouth in 5.3% of patients vs 2.3% with placebo

Dry Mouth was reported in 5.3% of patients given the weight loss drug, Belviq (lorcaserin), versus 2.3% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.

Read the entire article | Email this article
Posted by Larry Hobbs on Sat, Jun 22, 2013 1:50 pm | [0] comments

BELVIQ (lorcaserin)

Belviq (lorcaserin) side effects: Peripheral edema in 4.7% of patients vs 2.4% with placebo

Peripheral edema, or swelling of tissues, usually in the lower limbs, due to the accumulation of fluids, was reported in 4.7% of patients given the weight loss drug, Belviq (lorcaserin), versus 2.4% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.

Read the entire article | Email this article
Posted by Larry Hobbs on Sat, Jun 22, 2013 1:40 pm | [0] comments

BELVIQ (lorcaserin)

Belviq (lorcaserin) side effects: Cough in 4.3% of patients vs 3.4% with placebo

Cough was reported in 4.3% of patients given the weight loss drug, Belviq (lorcaserin), versus 3.4% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.

Read the entire article | Email this article
Posted by Larry Hobbs on Sat, Jun 22, 2013 1:34 pm | [0] comments

BELVIQ (lorcaserin)

Belviq (lorcaserin) side effects: Vomiting in 3.8% of patients vs 2.6% with placebo

Vomiting was reported in 3.8% of patients given the weight loss drug, Belviq (lorcaserin), versus 2.6% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.

Read the entire article | Email this article
Posted by Larry Hobbs on Sat, Jun 22, 2013 1:29 pm | [0] comments

BELVIQ (lorcaserin)

Belviq (lorcaserin) side effects: Anxiety in 3.5% of patients vs 3.2% with placebo

Anxiety were reported in 3.5% of patients given the weight loss drug, Belviq (lorcaserin), versus 3.2% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.

Read the entire article | Email this article
Posted by Larry Hobbs on Sat, Jun 22, 2013 1:29 pm | [0] comments

BELVIQ (lorcaserin)

Belviq (lorcaserin) side effects: Insomnia in 3.5% of patients vs 2.4% with placebo

Insomnia were reported in 3.5% of patients given the weight loss drug, Belviq (lorcaserin), versus 2.4% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.

Read the entire article | Email this article
Posted by Larry Hobbs on Sat, Jun 22, 2013 1:29 pm | [0] comments

BELVIQ (lorcaserin)

Belviq (lorcaserin) side effects: Depression in 2.3% of patients vs 2% with placebo

Depression were reported in 2.3% of patients given the weight loss drug, Belviq (lorcaserin), versus 2% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.

Read the entire article | Email this article
Posted by Larry Hobbs on Sat, Jun 22, 2013 1:29 pm | [0] comments

BELVIQ (lorcaserin)

Belviq (lorcaserin) side effects: Stress in 2.7% of patients vs 1.2% with placebo

Stress were reported in 2.7% of patients given the weight loss drug, Belviq (lorcaserin), versus 1.2% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.

Read the entire article | Email this article
Posted by Larry Hobbs on Sat, Jun 22, 2013 1:29 pm | [0] comments

BELVIQ (lorcaserin)

Belviq (lorcaserin) side effects: Seasonal allergy in 3.1% of patients vs 0.8% with placebo

Seasonal allergy was reported in 3.1% of patients given the weight loss drug, Belviq (lorcaserin), versus 0.8% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.

Read the entire article | Email this article
Posted by Larry Hobbs on Sat, Jun 22, 2013 1:28 pm | [0] comments

BELVIQ (lorcaserin)

Belviq (lorcaserin) side effects: Gastroenteritis in 3.1% of patients vs 2% with placebo

Gastroenteritis was reported in 3.1% of patients given the weight loss drug, Belviq (lorcaserin), versus 2% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.

Read the entire article | Email this article
Posted by Larry Hobbs on Sat, Jun 22, 2013 1:27 pm | [0] comments

BELVIQ (lorcaserin)

Belviq (lorcaserin) side effects: Pain in mouth or pharynx in 3.5% of patients vs 2.5% with placebo

Oropharyngeal pain which is pain in the mouth or pharynx was reported in 3.5% of patients given the weight loss drug, Belviq (lorcaserin), versus 2.5% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.

Read the entire article | Email this article
Posted by Larry Hobbs on Sat, Jun 22, 2013 1:26 pm | [0] comments

BELVIQ (lorcaserin)

Belviq (lorcaserin) side effects: Sinus congestion in 2.9% of patients vs 2.4% with placebo

Oropharyngeal pain which is pain in the mouth or pharynx was reported in 2.9% of patients given the weight loss drug, Belviq (lorcaserin), versus 2.4% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.

Read the entire article | Email this article
Posted by Larry Hobbs on Sat, Jun 22, 2013 1:23 pm | [0] comments

BELVIQ (lorcaserin)

Belviq (lorcaserin) side effects: Toothache in 2.7% of patients vs 0% with placebo

Toothache was reported in 2.7% of patients given the weight loss drug, Belviq (lorcaserin), versus 0% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.

Read the entire article | Email this article
Posted by Larry Hobbs on Sat, Jun 22, 2013 1:22 pm | [0] comments

BELVIQ (lorcaserin)

Belviq (lorcaserin) side effects: Worsening of diabetes in 2.7% of patients vs 0.8% with placebo

Worsening of diabetes mellitus was reported in 2.7% of patients given the weight loss drug, Belviq (lorcaserin), versus 0.8% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.

Read the entire article | Email this article
Posted by Larry Hobbs on Sat, Jun 22, 2013 1:21 pm | [0] comments

BELVIQ (lorcaserin)

Belviq (lorcaserin) side effects: Decreased appetite in 2.3% of patients vs 0.4% with placebo

Decreased appetite was reported in 2.3% of patients given the weight loss drug, Belviq (lorcaserin), versus 0.4% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.

Read the entire article | Email this article
Posted by Larry Hobbs on Sat, Jun 22, 2013 1:21 pm | [0] comments

Page 1 of 2. Go to page  1 2 >  Follow @fatnews

QUICKLINKS AND VIEW OPITONS

  • Categories of Articles
  • Summary View
  • Headline View
  • Archive of Quotes
  • Contact Us
  • QUOTE OF THE DAY

    Books by Larry Hobbs available on Amazon

    Book cover for The Case Against Statins

    © Copyright 2003-2021 - Larry Hobbs - All Rights Reserved.